CHMP Backs Novo Nordisk's FREHEMGO (denecimig) for Hemophilia A, Setting Up Late-2026 EU Launch
核心洞察
The EMA's CHMP recommended marketing authorization for FREHEMGO (搜索) (denecimig), a factor VIIIa (搜索) mimetic bispecific antibody for routine prophylaxis in hemophilia A (搜索).
The positive opinion covers adults and children with hemophilia A (搜索), with or without factor VIII inhibitors, using a prefilled pen dosed weekly, biweekly or monthly.
CHMP's decision rested on the phase 3 FRONTIER program, where mean annualized bleeding rates stayed below one and many patients had zero treated bleeds.
Novo Nordisk has secured a positive opinion from the European Medicines Agency (搜索)'s Committee for Medicinal Products for Human Use (CHMP) for FREHEMGO (搜索) (denecimig), a next-generation factor VIIIa (搜索) mimetic bispecific antibody for hemophilia A (搜索). The recommendation, announced Thursday, covers marketing authorization for routine prophylaxis to prevent or reduce bleeding episodes in adult and pediatric patients with hemophilia A, including those with or without factor VIII inhibitors.
The decision now rests with the European Commission, the EU's executive arm, which must grant final marketing authorization. Novo Nordisk said it expects to launch the medicine in the first European countries in the fourth quarter of 2026, followed by a broader rollout across the European Union in early 2027.
A Subcutaneous Prophylaxis With Flexible Dosing
FREHEMGO (搜索) is administered under the skin and is designed to "mimic" the role of factor VIIIa (搜索) by bridging factor IXa (搜索) and factor X. This action reproduces the cofactor function of FVIIIa, helping restore the body's thrombin generation capacity so that blood can clot. The therapy is designed to deliver once-monthly, every-two-weeks and weekly prophylaxis.
The recommended regimen allows patients to administer the medication weekly, biweekly or monthly using a single-use, prefilled pen injector. In the FRONTIER 5 study, nearly 97% of participants preferred the pen to their previous vial-and-syringe routine.
FRONTIER Program Data Underpin the Opinion
The CHMP opinion was based on data from the phase 3 FRONTIER clinical trial program, which includes FRONTIER 1–5 and investigates denecimig as a prophylactic treatment across pediatric and adult populations with hemophilia A (搜索), with or without inhibitors. FRONTIER 2, FRONTIER 3 and FRONTIER 4 formed the basis of the marketing authorization application.
In the pivotal FRONTIER 2 study, denecimig significantly reduced annualized bleeding rates compared with prior clotting factor prophylaxis and on-demand care in adults and adolescents aged 12 and older. FRONTIER 3 confirmed similar efficacy in children under 12. Across the entire program, mean annualized bleeding rates remained below one, and a substantial proportion of patients achieved zero treated bleeds. Trial results showed the therapy restored thrombin generation to normal ranges without inducing excessive clotting.
Additional studies examined other aspects of treatment. FRONTIER 4, an open-label extension trial, evaluated the efficacy of denecimig once every two weeks (Q2W) and investigated long-term safety across all dosing regimens — once monthly, once every two weeks and once every week — in subjects with hemophilia A (搜索), with or without inhibitors.
Switch Study Shows No New Safety Signals
Phase 3b data from FRONTIER 5, published in the Journal of Thrombosis and Haemostasis, showed that patients safely switched from emicizumab to denecimig without requiring a loading dose or washout period. In 61 adolescents and adults, the 26-week study found no unexpected safety issues, no blood clots and no side-effect-related dropouts. Clotting function rose into the normal range without signs of excessive clotting, and no new safety signals were identified following the treatment switch.
US Review Ongoing
Novo Nordisk submitted a Biologics License Application for denecimig to the U.S. Food and Drug Administration in September 2025. That review remains ongoing. The hemophilia franchise represents an area where Novo has invested more than four decades of development work.
Parallel Cardiometabolic Licensing Deal With Orbis Medicines
Separately, Novo Nordisk announced a strategic licensing agreement with Orbis Medicines (搜索), a biotech firm backed by Eli Lilly & Co., to design oral macrocycle drugs targeting cardiometabolic conditions. Under the terms of the deal, Orbis may receive up to $1.4 billion in upfront fees, milestone payments and tiered royalties. Novo Nordisk will also make a direct investment in Orbis, leveraging the partner's generative AI nGen platform to advance orally available therapeutics.
The collaboration signals Novo's intent to diversify beyond its established injectable franchises into oral treatment options for metabolic and cardiovascular diseases, and to broaden its revenue base beyond its blockbuster GLP-1 portfolio. The hemophilia recommendation provides a near-term commercial catalyst, while the Orbis collaboration represents a longer-term bet on oral drug delivery technology.
For Novo Nordisk, the European regulatory progress on FREHEMGO (搜索) reduces uncertainty around one of its key pipeline assets. A successful EU launch in late 2026 could add a new revenue stream in the hemophilia market, where Novo competes with established players. The next catalyst is European Commission approval and whether Novo can begin that first launch before year-end.